SCHEMBL4395849

SCHEMBL4395849

COC(C(N)=O)C(=O)N1CCCC1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 5/20 0.41
DPP4 P27487 5/20 0.41
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 4/20 0.33
HPGD P15428 2/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4394453 0.83 CYP3A4 (0.43) L3MBTL1ALDH1A1HPGDMMP1MMP3
SCHEMBL13359379 0.74 DPP7 (0.41) DPP7DPP4L3MBTL1ALDH1A1HPGD
SCHEMBL5918386 0.72 ALDH1A1 (0.42) DPP7DPP4ALDH1A1HPGDMMP1
SCHEMBL12539736 0.72 DPP4 (0.40) DPP7DPP4L3MBTL1ALDH1A1HPGD
SCHEMBL14744099 0.72 DPP7 (0.42) DPP7DPP4ALDH1A1HPGDMMP1
SCHEMBL6490935 0.72
SCHEMBL6167579 0.71 DPP4 (0.43) DPP7DPP4L3MBTL1HPGD
SCHEMBL27380670 0.71 DPP4 (0.43) DPP7DPP4L3MBTL1HPGD
SCHEMBL4395854 0.71 DPP7 (0.41) DPP7DPP4HPGDMMP1MMP2
SCHEMBL26124133 0.70 DPP7 (0.43) DPP7DPP4ALDH1A1HPGDMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090305382-A1 ALKOXY INDOLINONE BASED PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2009-12-10 US disclosed
US-7629339-B2 inhibitors of protein kinases and are useful in treating cancer; 4-({5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}-amino)-3-methoxy-butyric acid; anticarcinogenic agent THE SCRIPPS RESEARCH INSTITUTE (US) 2009-12-08 US disclosed
EP-1926725-A1 ALKOXY INDOLINONE BASED PROTEIN KINASE INHIBITORS The Scripps Research Institute (US) 2008-06-04 EP disclosed
WO-2007038251-A1 ALKOXY INDOLINONE BASED PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2007-04-05 WO disclosed
US-20070072934-A1 Alkoxy indolinone based protein kinase inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072934-A1 Alkoxy indolinone based protein kinase inhibitors PHKG1, MAP3K19, MAP3K20 DPP7 2064/4885DPP4 3319/4885L3MBTL1 2019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.